Product Description
BA1302 demonstrated excellent stability and antitumor potential both in vitro and in vivo. BA1302 is a novel CD228-directed ADC developed by Boan Biotech using its ADC platform technology. (Sourced from: https://www.boan-bio.com/en/phone/info.php?id=230)
Mechanisms of Action: CD228 Inhibitor
Novel Mechanism: Yes
Modality: Antibody Drug Conjugate
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Shandong Boan Biotechnology Co., Ltd.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|